Welcome to our dedicated page for Regenxbio news (Ticker: RGNX), a resource for investors and traders seeking the latest updates and insights on Regenxbio stock.
REGENXBIO Inc. reports news on its AAV gene therapy pipeline and manufacturing platform for rare, neuromuscular and retinal diseases. Recurring updates cover RGX-202 for Duchenne muscular dystrophy; clemidsogene lanparvovec (RGX-121) for MPS II; RGX-111 for MPS I; and surabgene lomparvovec (ABBV-RGX-314) for wet AMD and diabetic retinopathy.
Company announcements also include FDA regulatory communications, clinical and preclinical data presentations, financial results, operational highlights, and collaboration activity with partners including Nippon Shinyaku and AbbVie. News on the NAV and NAVXpress platforms addresses AAV vector technology, product quality, and manufacturing capabilities used across REGENXBIO's investigational programs.
REGENXBIO Inc. (Nasdaq: RGNX), a biotechnology firm focused on gene therapy, will host a conference call on August 6, 2020, at 4:30 p.m. ET, to discuss its financial results for Q2 2020, ending June 30, 2020.
The call will provide insights into the company's operational highlights and financial performance. Investors can participate by calling (800) 708-4539 (domestic) or (800) 619-6396 (international), or by accessing a live or recorded webcast on the REGENXBIO website.
REGENXBIO (Nasdaq: RGNX) announced on July 8, 2020, the completion of dosing three patients in Cohort 2 of its Phase I/II study of RGX-121 for Mucopolysaccharidosis Type II (MPS II). The data reported shows RGX-121 to be well-tolerated with no serious adverse events. The company also provided initial data on RGX-111 for MPS I, showing positive biochemistry results and sustained cognitive development in a patient treated. Both RGX-121 and RGX-111 are designed to improve outcomes in patients with rare genetic disorders, and further data updates are expected later this year.